摘要
目的观察左乙拉西坦片联合奥卡西平片治疗癫痫患者的疗效,探讨其对患者血清微小核糖核酸-222(miR-222)、B细胞活化因子(BAFF)水平的影响。方法选择2019年11月至2021年11月商洛市中心医院神经内科接诊的80例癫痫患者进行研究,按照随机数表法分为对照组和观察组各40例。对照组患者给予奥卡西平片治疗,观察组患者给予左乙拉西坦片联合奥卡西平片治疗,两组患者均持续治疗3个月。比较两组患者治疗后的疗效,以及治疗前后的血清miR-222、BAFF水平、神经功能指标和不良反应发生情况。结果观察组患者的治疗总有效率为95.00%,明显高于对照组的77.50%,差异有统计学意义(P<0.05);治疗前,两组患者的miR-222、BAFF水平比较差异均无统计学意义(P>0.05);治疗3个月后,观察组患者的miR-222、BAFF水平分别为0.87±0.16、(4.96±0.97)ng/mL,明显低于对照组的1.19±0.21、(7.49±2.04)ng/mL,差异均有统计学意义(P<0.05);治疗前,两组患者的S-100β蛋白(S-100β)、神经元特异性烯醇化酶(NES)、胶质纤维酸性蛋白(GFAP)水平比较差异均无统计学意义(P>0.05);治疗3个月后,观察组患者的S-100β、NES、GFAP水平分别为(0.41±0.03)μg/L、(10.01±2.12)ng/mL、(2.54±0.21)ng/L,明显低于对照组的(0.53±0.04)μg/L、(15.03±2.16)ng/mL、(3.21±0.14)ng/L,差异均有统计学意义(P<0.05);两组患者的不良反应总发生率比较差异无统计学意义(P>0.05)。结论左乙拉西坦片联合奥卡西平片治疗癫痫可改善患者的血清miR-222、BAFF水平,治疗效果显著,具有临床应用价值。
Objective To observe the curative effect of levetiracetam tablets combined with oxcarbazepine tablets in the treatment of patients with epilepsy,and to explore the effects of levetiracetam tablets on the levels of serum microribonucleic acid-222(miR-222)and B cell activating factor(BAFF)in patients with epilepsy.Methods From November 2019 to November 2021,80 patients with epilepsy admitted to Department of Neurology,Shangluo Central Hospital were selected and divided into the control group and the observation group according to random number table,each with 40 patients.The patients in the control group were treated with oxcarbazepine tablets,and the patients in the observation group were treated with levetiracetam tablets combined with oxcarbazepine tablets,both for 3 months.The curative effect,serum miR-222,BAFF levels,neurological function indicators,and adverse reactions of the two groups were compared before and after treatment.Results The total effective rate of the observation group was 95.00%,which was significantly higher than 77.50%of the control group(P<0.05).Before treatment,there was no significant difference in miR-222 and BAFF levels between the two groups(P>0.05);after 3 months of treatment,the levels of miR-222 and BAFF in the observation group were 0.87±0.16 and(4.96±0.97)ng/mL,which were significantly lower than 1.19±0.21 and(7.49±2.04)ng/mL in the control group(P<0.05).Before treatment,the levels of S-100βprotein(S-100β),neuron specific enolase(NES),and glial fibrillary acidic protein(GFAP)in the two groups had no statistically significant differ-ence(P>0.05);after 3 months of treatment,the levels of S-100β,NES,and GFAP in the observation group were(0.41±0.03)μg/L,(10.01±2.12)ng/mL,(2.54±0.21)ng/L,significantly lower than(0.53±0.04)μg/L,(15.03±2.16)ng/mL,(3.21±0.14)ng/L in the control group(P<0.05).The total incidence of adverse reactions in the two groups showed no sta-tistically significant difference(P>0.05).Conclusion Levetiracetam tablets combined with oxcarbazepine tablets can improve the serum miR-222 and BAFF levels in patients with epilepsy,with significant treatment effect,which is wor-thy of clinical application.
作者
席光明
陈召东
XI Guang-ming;CHEN Zhao-dong(Second Department of Neurology,Shangluo Central Hospital,Shangluo 726000,Shaanxi,CHINA;First Department of Neurology,Shangluo Central Hospital,Shangluo 726000,Shaanxi,CHINA)
出处
《海南医学》
CAS
2023年第3期318-321,共4页
Hainan Medical Journal
基金
陕西省科技攻关项目(编号:2010K21393)。
